Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT05417399
Recruiting Observational

Influence of Hawthorne Effect and Dual-tasks on Gait in CP

NCT05417399 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Roessingh Research and Development
Phase
Observational
Started
2022-09-01
Last updated
2026-07-13

Condition(s) studied

Cerebral PalsyGait Disorders, NeurologicHawthorne EffectDual-tasksKinematics

Study summary

It is the clinical experience of the authors that some children with cerebral palsy who walk in crouch gait show sufficient knee extension during the clinical gait analysis, but walk in considerable knee flexion when they leave the gait laboratory. Possible differences between walking in a gait lab and walking in daily life may be caused by the effect of observational awareness in the lab (also known as the Hawthorne effect), and the lack of dual-tasks (DT) during the analysis (which are common during daily life walking). Since so far there is no technique to reliably measure gait kinematics in children with CP outside of the laboratory, the researchers aim to objectify the influence of both the Hawthorne effect and dual-tasks by introducing different conditions during a standard clinical 3D gait analysis.

Eligibility

Sex
ALL
Min age
4 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Cerebral palsy, bilateral spastic, GMFCS classification I-III * Age \<16 years * Use of bilateral AFO's (rigid or ground reaction AFO's) to improve knee extension in stance Exclusion Criteria: * Behavioural issues or poor instructability which might affect participation in the protocol * Significant visual disorders * Other diagnoses influencing gait * Not willing to sign informed consent before inclusion

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Roessingh Research and Development Enschede Overijssel Recruiting

More Roessingh Research and Development trials in the Netherlands

Technical Evaluation of Commercial IMUs Within Clinical Gait Analysis Recruiting
Arm Use With Soft-robotic Glove Recruiting

Other trials for the same condition

European Newborn Study: Early Markers for a Better LifE Recruiting
GUIDed Growth of the Proximal Femur to Prevent Further Hip MigrAtion in CErebral Palsy Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05417399 on ClinicalTrials.gov ↗ ← All trials in the Netherlands